Abstract: Immunogenic polysaccharide-protein conjugates are generated which have an oxidized polysaccharide derived from the capsular polysaccharide of Streptococcal pneumniae and the pneumolysin protein of S. pneumoniae which is expressed recombinantly. The pneumolysin is not toxoided prior to conjugation with said oxidized polysaccharide. The immunogenic conjugates are used as vaccines to elicit antibody responses to the capsular polysaccharide of S. pneumoniae and to recombinant pneumolysin, and to immunize against S. pneumoniae-caused disease.

Abstract: A combined vaccine for eliciting polyribosyl ribitol phosphate (PRP) antibody formations in warm-blooded animals has been invented. The combined vaccine comprises the capsular polysaccharide PRP isolated and purified from Haemophilus influenzae type b and antigens isolated and purified from an outer membrane component of Bordetella pertussis.A method for inducing active immunization in warm-blooded animals against systemic infection caused by the pathogen H. influenzae type b has also been invented. The method comprises administering an immunogenic amount of a combined vaccine comprising the capsular polysaccharide PRP isolated and purified from H. influenzae type b and antigens isolated and purified from an outer membrane component of B. pertussis.

Abstract: A multivalent pneumococcal vaccine of the group consisting of immunogenic amounts of purified pneumococcal capsular polysaccharide (substantially absent "C" polysaccharide) of pneumococcal types (Danish designation) 1, 2, 3, 4, 6A, 6B, 7F, 8, 9N, 12F, 14, 18C, 19F, 20, 23F, and 25 and combinations thereof and methods of purifying pneumococcal capsular polysaccharide types 1, 2, 3, 4, 6A, 6B, 7F, 8, 9N, 12F, 14, 18C, 19F, 23F and 25.

Abstract: A process for the isolation and purification of immunologically active polyribosyl ribitol phosphate (PRP), the capsular polysaccharide of Haemophilus influenzae type b. The PRP has been purified with ethanol, Cetavlon (hexadecyltrimethyl ammonium bromide) and a phosphate containing adsorbent, hydroxylapatite. The contaminants (nucleic acid, proteins and endotoxins) are removed to the minimum level by a treatment with hydroxylapatite. Also described is a process for the preparation of a combined vaccine containing the PRP (prepared as aforementioned) and B. pertussis antigens. The vaccine elicits anti-PRP antibody and antipertussis antibody (as measured by microagglutination) formations in young animals. This sera with anti-PRP antibody exhibits a strong bactericidal activity.